Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.
Share:
More In Business
Taylor Swift Threatens to Sue the College Student Tracking Her Private Jet
Taylor Swift’s camp is hitting Jack Sweeney, a junior at the University of Central Florida, with a cease-and-desist letter that blamed his automated tracking of her private jet for tipping off stalkers as to her location.
BetMGM Is Betting Big on Super Bowl LVIII
Adam Greenblatt, CEO of BetMGM shares the company’s plans for the big game, the growth of sports betting across the U.S., and more.
A.I.-Assisted Search and ‘Unhinged’ Marketing: The Future of Digital Marketplaces
Courtney Chow, Battery Ventures Vice President, breaks down why there are still new opportunities for digital marketplaces to grow.
Why Now Is a Good Time to Invest
Surprise, surprise: tech is still the sector to watch, according to Karyn Cavanaugh, Chief Investment Officer at Carolinas Wealth Management. Learn how to properly diversify your portfolio.
Is This Picture Real or AI? Meta Will Answer That For You
Facebook and Instagram users will start seeing labels on AI-generated images in their feeds. Hopefully this will save time for everyone zooming in each picture to see how many fingers someone's hand has.
Why Now is a Crucial Time to Pay Off Credit Card Debt
Inflation and loans and rates — oh my! If you're dealing with credit card debt, you aren't alone. These are some ways to pop the debt balloon.
Safety Recalls for Two Automakers: Are You Affected?
Drivers of these recalled vehicles who don't read this article will know they're affected starting March 18.
Seabound Wants to End Commercial Shipping Emissions
Alisha Fredriksson, CEO and co-founder of Seabound, discusses the carbon capture company’s successful maiden voyage and its plans for growth.
Where Does Spotify Go From Here?
Seth Schachner, Managing Director at StratAmericas, weighs in on Spotify earnings and why that headline-grabbing deal with Joe Rogan could be worth that $250 million.
